BioSpace News Archive

The growth of the global immunofluorescence assay market is ascribed to the rising prevalence of various chronic illnesses.

SAGA Diagnostics AB, a cancer liquid biopsy and genomic testing company, announced that it has raised SEK 106 million in a Series A2 financing from both existing and new investors.

CN Bio, a leading Organ-on-a-chip Company that designs and manufactures single and multi-organ microphysiological systems, announced that King’s College London, an internationally renowned research university, has adopted the PhysioMimix™ Multi-Organ MPS.

AbbVie (NYSE: ABBV) today announced that upadacitinib (15 mg or 30 mg, once daily) met the primary endpoint of clinical remission (per Adapted Mayo Score) and all secondary endpoints at one-year (week 52) in the Phase 3 ulcerative colitis maintenance study

Cancer Targeted Technology (CTT), a privately held Seattle-based biotechnology company, received a milestone payment from Advanced Accelerator Applications International S.A. (AAA), a Novartis company, triggered by the upcoming clinical trials of investigational 18F-CTT1057, a diagnostic PET imaging agent for prostate cancer.